Sun Pharma
Sun Pharma share price in focus on Monday after Trump's tariff announcement
Sun Pharma shares will be in focus on April 6 due to President Trump's new executive order imposing 100% tariffs on imported branded drugs unless companies lower prices or produce domestically. Jefferies reports that Sun Pharma may only face up to 15% tariffs on its innovative products.
2 min read3 Apr 2026India’s weight-loss drug rush kicks off with generics 50-90% cheaper
Top drugmakers roll out cheaper semaglutide within a day of patent expiry, triggering a scramble for share in India's weight-loss and diabetes market.
4 min read21 Mar 2026Natco Pharma fires first shot in weight-loss drug price war; generic semaglutide to cost 90% less at ₹1,290 per month
With other major players like Sun Pharma and Dr Reddy's also set to launch, the entry of Natco's ₹1,290 per month vial signals a significant shift in affordability.
2 min read20 Mar 2026When Dilip Shanghvi, Yusuf Hamied, Vinita Gupta, GV Prasad, other doyens discussed the future of Indian Pharma
The occasion was the launch of Made in India, a biography of Lupin's late founder Desh Bandhu Gupta, chronicling his life and, through it, the rise of the Indian pharmaceutical industry itself.
5 min read10 Feb 2026Why Sun Pharma’s hefty bid for Organon has divided investors
The potential $10-billion deal has split the market, pitting those who trust chairman Dilip Shanghvi’s track record of value creation against skeptics wary of Organon’s $8.9 billion debt pile and recent governance issues.
4 min read21 Jan 2026LIC raises stake in Sun Pharma to 5.04%. Details here
LIC bought 2,02,500 shares of Sun Pharma from the open market, amounting to a 0.008% stake, from the open market on January 13. With this, LIC's stake in the blue-chip pharma stock has jumped to 5.004% from 4.996% earlier.
1 min read14 Jan 2026Mint Explainer: Why do Indian drug makers challenge global giants' patents?
Indian drugmakers primarily produce generics, or copycat versions, and in order to enter the market, they either have to wait for patents to expire or challenge the innovator’s rights.
4 min read6 Jan 2026Ajanta Pharma ties up with Biocon to sell generic semaglutide in overseas market
Ajanta Pharma plans to sell generic semaglutide in 26 countries, in a partnership with Biocon, capitalizing on patent expirations. With a strong foothold in emerging markets and a potential 10x market growth, Ajanta aims to become a leading player in the global GLP-1 market by 2027.
3 min read23 Dec 2025Bangladesh gets a head start over India in export of weight-loss drugs to emerging markets
As Indian drug giants rush to export weight-loss drug semaglutide in countries that don’t have patent exclusivity, they face an unlikely adversary in their neighbour.
5 min read19 Dec 2025Sun Pharma share price falls 3% after US FDA conducts inspection in Baska facility. Should you buy, sell or hold?
According to an exchange filing, the pharma major said the inspection took place between September 8 and September 19, 2025, following which the US FDA classified the facility under Official Action Indicated (OAI) status.
2 min read18 Dec 2025